Inflammation in psoriasis is driven through the IL‐23/IL‐17 pathway. Monoclonal antibodies targeting cytokines in the pathway have proven highly effective and are widely used in clinical practice. There is still much to learn, however, about how these pathogenic responses are controlled, particularly with respect to the highly immunologically active molecules produced by the inflamed skin tissue itself. These tissue‐derived molecules, which include IL‐33, play important roles in modulating chronic inflammation that we are only beginning to understand. Here we highlight new research indicating a role for IL‐33 in modulating the inflammatory Th17 response in psoriasis, which may provide avenues for developing new psoriasis treatments.

中文翻译：

---

发炎的银屑病皮肤中的 T 细胞和细胞因子。谁负责？

银屑病的炎症是通过 IL-23/IL-17 途径驱动的。针对该通路中细胞因子的单克隆抗体已被证明非常有效，并广泛用于临床实践。然而，关于如何控制这些致病反应，特别是关于由发炎的皮肤组织本身产生的高免疫活性分子，仍有很多需要学习的地方。这些组织衍生的分子，包括 IL-33，在调节我们才刚刚开始了解的慢性炎症方面发挥着重要作用。在这里，我们强调了新研究表明 IL-33 在调节银屑病中的炎症性 Th17 反应中的作用，这可能为开发新的银屑病治疗提供途径。